共 98 条
[1]
Hasumi Y(2007)Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling Int J Cancer 121 2606-2614
[2]
Klosowska-Wardega A(2006)Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 Mol Cancer Ther 5 1280-1289
[3]
Furuhashi M(2005)Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas Cancer Res 65 7241-7248
[4]
Ostman A(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550
[5]
Heldin CH(2005)Docetaxel for treatment of solid tumours: a systematic review of clinical data Lancet Oncol 6 229-239
[6]
Hellberg C(2006)Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329-1338
[7]
Potapova O(2006)Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16-24
[8]
Laird AD(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124
[9]
Nannini MA(2003)SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 471-478
[10]
Shikada Y(2006)An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases J Clin Endocrinol Metab 91 4070-4076